Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
BMC Ophthalmol ; 22(1): 173, 2022 Apr 18.
Artículo en Inglés | MEDLINE | ID: mdl-35436870

RESUMEN

PURPOSE: To compare 6 methods for intraoperative pupil dilatation in eyes with insufficient pupil size during phacoemulsification. METHODS: This was a prospective case-control study. 99 microcoria cataract patients (120 eyes) were collected and were divided into 6 groups(20 eyes each group), and their pupils were dilated by bimanual stretching pupil (group I), pupil radial cut open(group II), mechanical pupil dilatation with iris-retractor hooks (group III), OASIS iris expander (group IV), and Malyguin-ring (Microsurgical company, America) (group V), B-HEX Pupil Expander (Med Invent Devics, India)(group VI),respectively. 3.0 mm clear corneal incision were used in phacoemulsification. All cases were followed up at 1 week and 1, 3, 6 months after the surgery. The best corrected visual acuity (BCVA), intraocular pressure(IOP), corneal endothelium cell density(ECD), pupil diameter(PD) of before and after surgery were compared. RESULTS: One same doctor finished all cataract surgeries successfully. The eyes' condition before surgery and at 6 months after surgery were compared. There were no significant statistical differences for the conditions of the eyes before surgery among six groups. The ECDs were better at 6 months postoperatively in group III and V, median values: 2114/mm2, 1961/mm2. PD was largest in group II (median value: 5.5 mm), which was significantly larger than other groups (Padjusted < 0.05). CONCLUSIONS: All 6 methods used in this study were effective for the mechanical dilatation of small pupils and didn't affect the postoperative visual acuity and intraocular pressure in microcoria cataract phacoemulsification. Iris-retractor hooks and the Malyugin Ring can reduce intraoperative corneal endothelium cell loss. Postoperative PD is larger when the iris was cut open radially.


Asunto(s)
Catarata , Enfermedades del Iris , Midriasis , Facoemulsificación , Trastornos de la Pupila , Estudios de Casos y Controles , Dilatación , Anomalías del Ojo , Humanos , Enfermedades del Iris/cirugía , Implantación de Lentes Intraoculares/métodos , Miosis/cirugía , Facoemulsificación/métodos , Trastornos de la Pupila/cirugía
2.
Int J Clin Pract ; 75(8): e14272, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-33908134

RESUMEN

PURPOSE: To observe the effect of phacoemulsification and intraocular lens (IOL) implantation with or without lens capsular tension ring (CTR) on retinitis pigmentosa (RP) combined with cataract patients. DESIGN: Retrospective cases series study. METHODS: Sixty-three cases (84 eyes) of RP with cataract were collected, including 30 males and 33 females. Phacoemulsification with 3.0 mm clear corneal incision was performed in all the patients. IOL and CTR implantation were performed in 44 eyes, and IOL implantation alone was performed in 40 eyes. All cases were followed up at 1 day, 1 week and 1, 3, 6,12 months after the surgery to compare the best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal endothelial cell count (ECC) and complications before and after the surgery. RESULTS: All surgery were successfully completed by the same physician, and IOL and CTR were all implanted in capsule without complications. The BCVA at 6 months after surgery was 0.91 ± 0.88 LogMAR, showing an improvement compared with the BCVA(1.3 ± 0.7LogMAR) before surgery and there was a statistically significant difference (P = .003). Four cases of capsule contraction syndrome (CCS) occurred in no CTR implantation group and there was no CCS in CTR group. There was a statistically significant difference in the incidence of CCS between two groups (P = .047). CONCLUSIONS: Phacoemulsification for RP combined with cataract is safe and reliable, and CTR implantation is conducive to reducing the complications caused by capsule contraction.


Asunto(s)
Catarata , Cápsula del Cristalino , Retinitis Pigmentosa , Catarata/complicaciones , Femenino , Humanos , Cápsula del Cristalino/cirugía , Implantación de Lentes Intraoculares , Masculino , Complicaciones Posoperatorias/prevención & control , Retinitis Pigmentosa/complicaciones , Estudios Retrospectivos
4.
Sci China Life Sci ; 63(12): 1928-1937, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32399769

RESUMEN

The purpose of this study was to investigate the role of a human lens microRNA (miR-497-5p) in regulating epithelialmesenchymal transition (EMT) under the control of transforming growth factor beta (TGF-ß). A microRNA array was used to evaluate the microRNA profiles of untreated and TGF-ß-treated human lens epithelial cells in culture. This showed that TGF-ß treatment led to the upregulation of 96 microRNAs and downregulation of 39 microRNAs. Thirteen microRNAs were predicted to be involved in the pathogenesis of posterior capsule opacification (PCO). Meanwhile, overexpression of miR-497-5p suppressed cell proliferation and EMT 48 h post-transfection, and inhibition of miR-497-5p accelerated cell proliferation and EMT. Treatment with TGF-ß inhibited the expression of miR-497-5p, but not cell proliferation. miR-497-5p was also found to regulate the level of CCNE1 and FGF7, which are reported to be actively involved in EMT. CCNE1 and FGF7 were bona fide targets of miR-497-5p. The results suggest that miR-497-5p participates in the direct regulation of lens epithelial cell EMT and is regulated by TGF-ß. miR-497-5p may be a novel target for PCO therapy.


Asunto(s)
Transición Epitelial-Mesenquimal/efectos de los fármacos , Cristalino/efectos de los fármacos , MicroARNs/genética , Factor de Crecimiento Transformador beta/farmacología , Opacificación Capsular/genética , Opacificación Capsular/metabolismo , Opacificación Capsular/patología , Línea Celular , Proliferación Celular/efectos de los fármacos , Ciclina E/genética , Ciclina E/metabolismo , Células Epiteliales , Factor 7 de Crecimiento de Fibroblastos/genética , Factor 7 de Crecimiento de Fibroblastos/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Cristalino/citología , Cristalino/metabolismo , MicroARNs/metabolismo , Proteínas Oncogénicas/genética , Proteínas Oncogénicas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA